Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Smooth Muscle Relaxants" patented technology

List smooth muscle relaxants or antispasmodics which would be prescribed for diverticulitis? Asked 24 Apr 2010 by patm2736 Updated 24 April 2010 Topics antispasmodic, diverticulitis

Compositions and methods for the treatment of anorectal disorders

Compositions and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide (O2−) scavengers, β-adrenergic agonists, cAMP-dependent protein kinase activators, α1-adrenergic antagonists, L-type Ca2+ channel blockers, estrogens, ATP-sensitive K+ channel activators and smooth muscle relaxants are used.
Owner:STREHKEHN INT LTD

Medicine comprising dicyanopyridine derivative

InactiveUS20030232860A1Good effectBiocideOrganic chemistryBladder baseK channels
Compounds having a high conductance-type of calcium-activated K channel opening effect and a smooth muscle relaxant effect for bladder based on the K-channel opening effect, which can be used in treating pollakiuria and urinary incontinence, are provided. 3,5-Dicyanopyridine derivatives or their salts.
Owner:ASTELLAS PHARMA INC

Methods for treating urinary incontinence and other disorders using trospium

InactiveUS20050043342A1Potent activityAvoiding concomitant liabilityBiocideAnimal repellantsDiseaseSide effect
Methods are disclosed using Trospium Chloride, an antimuscarinic smooth muscle relaxant, for the treatment of urinary incontinence, and other disorders, while avoiding the concomitant liability of adverse side effects associated with other antimuscarinic drugs.
Owner:BRIDGE PHARMA INC

Nitrosated and nitrosylated heme proteins

InactiveUS7033999B2BiocideDipeptide ingredientsNitrosoVascular smooth muscle relaxation
Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-heme proteins, S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoproteins; and S-nitroso-immunoglobulins. The invention also relates to therapeutic use if S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body. The invention also relates to the nitrosylation of oxygen, carbon and nitrogen moieties present on proteins and amino acids, and the use thereof to achieve the above physiological effects.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Methods for treating smooth muscle contractions using trospium

InactiveUS20060293356A1Potent activitySafely be used as treatmentBiocideMuscular disorderDiseaseSide effect
Methods are disclosed using trospium, an antimuscarinic smooth muscle relaxant, for the treatment of smooth muscle disorders, while avoiding the concomitant liability of adverse side effects associated with conventional antimuscarinic treatment.
Owner:BRIDGE PHARMA INC

Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality

InactiveUS20060198831A1Inhibiting platelet functionPeptide/protein ingredientsSerum albuminVascular smooth muscle relaxationPlatelet inhibition
Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body. The invention also relates to the nitrosylation of oxygen, carbon and nitrogen moieties present on proteins and amino acids, and the use thereof to achieve the above physiological effects.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Methods for relaxation of smooth muscle contractions using Trospium

Methods are disclosed using Trospium Chloride, an antimuscarinic smooth muscle relaxant, for the treatment of urinary incontnence, while avoiding the concomitant liability of adverse side effect associated with other antimuscarinic drugs.
Owner:BRIDGE PHARMA INC

Extended release matrix tablets

The present invention relates to extended release matrix tablets for oral administration that include a cationic polymer, a water-swellable polymer, and an alginic acid derivative to cause the release rate of the active ingredient of the tablets to be independent of pH and gastric residence time. The active pharmaceutical ingredient may be one or more of antibiotics, sympathomimetics, sympatholytic agents, cholinergic agents, antimuscarinics, gastro-intestinal drugs, gentio-urinary smooth muscle relaxants, cardiac drugs, anticonvulsants, tranquilizers and sedatives, and in particular may be an antibiotic, such as cefaclor, or may be a sympatholytic agent, such as carvedilol.
Owner:RANBAXY LAB LTD

Combination therapy for male sexual dysfunction

InactiveUS20170326139A1Reliable and effective and convenient on demand treatmentImproves overall sexual well-beingPill deliveryAmide active ingredientsTadalafilEscitalopram
Pharmaceutical formulations containing a serotonin reuptake inhibitor and a smooth muscle relaxant are provided for the treatment of premature ejaculation and the increase in intravaginal ejaculatory latency time. Specific formulations contain tadalafil (1-30 mg per dose) or tamsulosin (0.05-2 mg) and escitalopram (1-30 mg) in daily dose and on-demand formulations.
Owner:ATP THERAPEUTICS

Compositions and methods for treatment of anorectal disorders

Compositions and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide (O2-) scavengers, beta-adrenergic agonists, cAMP-dependent protein kinase activators, alpha1-adrenergic antagonists, L-type Ca2+ channel blockers, estrogens, ATP-sensitive K+ channel activators and smooth muscle relaxants are used.
Owner:思特肯有限公司

Vasodilator Eluting Luminal Stent Devices With A Specific Polyphosphazene Coating and Methods for Their Manufacture and Use

InactiveUS20080138377A1Avoid accumulationAntibacterial and anti-inflammatory propertyBiocideSurgeryPolyphosphazeneVascular dilatation
The present invention is directed to luminal stent devices including vascular devices that comprise a specific polyphosphazene and the capability of releasing nitric oxide or other smooth muscle relaxant compounds in vivo or into stored or transient flowing blood to achieve vascular dilatation, reduce adverse reactions, reduce thrombosis, and / or to maintain the patency of a desired anatomic lumen.
Owner:CELONOVA BIOSCIENCES INC

Vasodilator eluting blood storage and administration devices with a specific polyphosphazene coating and methods for their manufacture and use

The present invention is directed to medical devices including blood storage and handling products that comprise a specific polyphosphazene and the capability of releasing nitric oxide or other smooth muscle relaxant compounds in vivo or into stored or transient flowing blood to achieve vascular dilatation, reduced adverse reactions, reduced thrombosis, reduced incidence of post-transfusion acute myocardial infarctions, and / or to improve blood storage capabilities.
Owner:CELONOVA BIOSCIENCES INC

Ethyl nitrite as a gastrointestinal smooth muscle relaxant and diagnostic and therapeutic uses thereof

The present invention provides compositions comprising a gas and a gastrointestinal smooth muscle relaxing agent comprising ethyl nitrite in a therapeutically effective amount. The present invention also provides methods of relaxing gastrointestinal smooth muscle, alleviating contraction or spasm of gastrointestinal smooth muscle to facilitate a diagnostic medical procedure and treating or preventing a gastrointestinal disorder using the compositions of the invention.
Owner:DUKE UNIV

Method for the treatment of urinary incontinence

Urinary incontinence is alleviated in a mammal by administering to the mammal a urinary incontinence alleviating amount of dextromethorphan, dextrorphan, their mixtures and / or pharmaceutically acceptable salts, alone or in combination with a pharmacologically active agent such as an anticholinergic, sympathomimetic, tricyclic antidepressant, antispasmodic, direct-acting smooth muscle relaxant, estrogen, compound having estrogen-like activity, or any combination of the foregoing.
Owner:ENDO PHARMA INC

Vasodilator eluting medical devices with a specific polyphosphazene coating and methods for their manufacture and use

The present invention is directed to medical devices in which flow is channeled of blood and blood products for the purpose of effecting a chemical exchange to remove desired chemicals from the blood or blood products, and to impart nitric oxide, other smooth muscle relaxant compounds, or other desired chemicals to the blood or blood products to achieve vascular dilatation, reduce adverse reactions, reduce thrombosis, reduce red blood cell injuries, and improve blood handling capabilities. In the present invention, such chemical exchanges occur over semipermeable membranes associated with channeled flow of blood and blood products. Various embodiments of the present invention thus apply to the clinical settings for filters, cannulae, tubing, and blood handling components for dynamic blood handling, filtering, and processing devices including, but not limited to, cardiopulmonary bypass pumps, left ventricular assist devices, artificial hearts, ECMO devices, renal or hepatic hemodialysis systems, and hemofiltration systems.
Owner:CELONOVA BIOSCIENCES INC

Methods for treating smooth muscle disorders using trospium

InactiveUS20060287347A1Improved pharmacokinetic profileStable plasma levelBiocideMuscular disorderDiseaseSide effect
Methods are disclosed using Trospium Chloride, an antimuscarinic smooth muscle relaxant, for the treatment of urinary incontinence, and other disorders, while avoiding the concomitant liability of adverse side effects associated with conventional antimuscarinic treatment.
Owner:BRIDGE PHARMA INC

Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents

InactiveUS20090227672A1Remarkable effectLow ocular surfaceBiocideSenses disorderDiseaseEther
The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
Owner:ALLERGAN INC

Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

The present invention provides to cyclopentane heptanoic acid, 2 heteroaryl alkyl or alkenyl derivatives which may be substituted in the 1-position with hydroxyl, alkyloxy, amino and amino groups, e.g. 1-OH cyclopentane heptanoic acid, 2 heteroarylalkenyl derivatives. In particular, these derivatives are 7-[5-hydroxy-2-(heteroatom-substituted hydroxyhydrocarbyl)-3-hydroxycyclopentyl] heptanoic or heptenoic acids and amine, amide, ether, ester and alcohol derivatives of said acids wherein one or more of said hydroxy groups are replaced with an ether group. These compounds are potent ocular hypotensive and are particularly suited for the management of glaucoma. Moreover, the compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; with additional application in gastrointestinal disease, reproduction, fertility, incontinence, shock, inflammation, immune regulation, disorder of bone metabolism, renal dysfunction, cancer and other hypoproliferative diseases.
Owner:ALLERGAN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products